FINWIRES · TerminalLIVE
FINWIRES

米イラン協議第2回開催の可能性を受け、中国株が急騰

-- ドナルド・トランプ米大統領がホルムズ海峡封鎖を示唆したことを受け、米イラン間の緊張緩和への期待感から中国株は上昇した。 上海総合指数は1%(38.07ポイント)上昇し、火曜日の取引を4,026.63で終えた。深セン成分指数は1.6%(232.09ポイント)上昇し、14,639.95となった。 パキスタンでの交渉が決裂したにもかかわらず、米イランが依然として意思疎通を図っており、2回目の直接会談の可能性もあるとの報道を受け、市場心理は改善した。トランプ大統領は、イランは封鎖が有効な状況下で米国と「合意を目指したい」と述べている。 企業ニュースでは、中国精密工業(SHE:002046)が、第1四半期に800万元から1200万元の株主帰属損失を計上する見込みとの見通しを発表したことを受け、株価が5.8%上昇した。 河南神火煤電(SHE:000933)は、第1四半期の株主帰属純利益が前年同期比223%増の22億9000万元に急増したことを受け、株価が4.4%上昇した。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF